{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:22:29Z","timestamp":1777681349298,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Introduction: Due to the abbreviated approval pathway and extrapolation to non-studied indications, an increased importance is placed on post-marketing surveillance of biosimilars to supplement existing evidence and enhance patient and provider confidence. Bevacizumab-awwb (ABP 215, Mvasi) was the first biosimilar approved to bevacizumab (Avastin), a recombinant humanized monoclonal IgG1 antibody that inhibits the vascular endothelial growth factor (VEGF). Purpose: To evaluate utilization, safety, and financial outcomes of bevacizumab-awwb compared to bevacizumab at a national cancer institute (NCI)-designated cancer center. Methods: A single center, retrospective, 1:1 indication-matched cohort study of adult patients who received bevacizumab or bevacizumab-awwb between October 1, 2019 and October 1, 2020 was performed. Thirty-four patients received bevacizumab-awwb during the study period and were matched by indication to 34 randomly selected patients who received bevacizumab. Indications for both groups included: colorectal cancer (n\u2009=\u200919), gynecologic cancer (n\u2009=\u200910), glioblastoma (n\u2009=\u20093), hepatocellular carcinoma (n\u2009=\u20091), and lung cancer (n\u2009=\u20091). Results: Baseline and medication utilization characteristics were similar for this indication-matched cohort of 68 patients receiving bevacizumab-awwb or bevacizumab. Patients in the bevacizumab group had a higher proportion of public payer coverage (64.7% vs 38.2%, P\u2009=\u2009.029). A higher proportion of patients in the bevacizumab-awwb group remained on active treatment at the end of the study period (52.9%) as compared to the bevacizumab group (35.3%); however, differences in final treatment status and reasons for discontinuation were not statistically significant ( P\u2009=\u2009.218). Rates of worsened hypertension (44.1% vs 44.1%) and worsened proteinuria (38.2% vs 23.5%, P\u2009=\u2009.077) were common in both groups. Grade 3 adverse drug events in the bevacizumab group included: gastrointestinal perforation (n\u2009=\u20091), gastrointestinal bleed (n\u2009=\u20091), hypertension (n\u2009=\u20092), and venous thromboembolism (n\u2009=\u20092). Grade 3 adverse drug events in the bevacizumab-awwb group included: epistaxis (n\u2009=\u20091), gastrointestinal bleed (n\u2009=\u20091), hypertension (n\u2009=\u20091), intracerebral hemorrhage (n\u2009=\u20091), venous thromboembolism (n\u2009=\u20093), and arterial thromboembolism (n\u2009=\u20091). One patient in the bevacizumab-awwb group experienced grade 4 hypertension. Median drug cost per dose and per milligram for bevacizumab-awwb was less than bevacizumab, representing a 15.8% and 12.1% discount, respectively. Conclusion: Utilization and safety outcomes were similar for this indication-matched cohort of 68 patients receiving bevacizumab or bevacizumab-awwb across a wide range of disease states.<\/jats:p>","DOI":"10.1177\/00185787211046865","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T01:49:58Z","timestamp":1631843398000},"page":"455-461","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-147X","authenticated-orcid":false,"given":"Jennifer Philippon","family":"Booth","sequence":"first","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-3849","authenticated-orcid":false,"given":"Jeffrey","family":"Pilz","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"bibr1-00185787211046865","unstructured":"Food and Drug Administration. Biosimilar and interchangeable products. October 23, 2017. Accessed October 2, 2020. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-and-interchangeable-products"},{"key":"bibr2-00185787211046865","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMhle1800125"},{"key":"bibr3-00185787211046865","unstructured":"Food and Drug Administration. Biosimilar product information: FDA-approved biosimilar products. July 7, 2020. Accessed October 2, 2020. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"bibr4-00185787211046865","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.4893"},{"key":"bibr5-00185787211046865","unstructured":"AVASTIN (bevacizumab) prescribing information Food and Drug Administration. Genentech Inc; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125085s0169lbl.pdf"},{"key":"bibr6-00185787211046865","unstructured":"MVASI (bevacizumab-awwb) prescribing information. Food and Drug Administration. Amgen Inc; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761028s000lbl.pdf"},{"key":"bibr7-00185787211046865","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1452580"},{"key":"bibr8-00185787211046865","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu331.49"},{"key":"bibr9-00185787211046865","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3457-8"},{"key":"bibr10-00185787211046865","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3695-4"},{"key":"bibr11-00185787211046865","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1098"},{"key":"bibr12-00185787211046865","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0125"},{"key":"bibr13-00185787211046865","unstructured":"U.S. Department of Health and Human Services \u2013 National Institutes of Health \u2013 National Cancer Institute. Common terminology criteria for adverse events (CTCAE): version 5.0. Published November 27, 2017. Accessed October 12, 2020. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787211046865","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787211046865","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787211046865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:39:41Z","timestamp":1777451981000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787211046865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/00185787211046865"],"URL":"https:\/\/doi.org\/10.1177\/00185787211046865","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}